June 26th, 2023, Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.
As leaders in their respective fields, this strategic partnership marks an important milestone in both companies’ business growth and development. Also, it’s a strategic move in enabling their customers across the world. Moving forward, WuXi Biologics and Pharmadule Morimatsu will continue to explore further cooperation and seek more collaborations opportunities on a global basis.
WuXi Biologics is a leading global CRDMO company. Leveraging its comprehensive open-access platform, WuXi Biologics provides end-to-end research, development and manufacturing services for monoclonal antibodies, bispecifics, ADCs, vaccines and other biological drugs to its global clients. Since 1986, Pharmadule Morimatsu has successfully delivered more than 80 modular facilities to the pharmaceutical and biopharmaceutical industries worldwide. In recent years, Pharmadule Morimatsu has delivered a large number of modular production modules and skids for the production of different types of advanced biological drugs to the United States, China, Morocco, Egypt, Mexico and other countries. Pharmadule Morimatsu provides the clients with “core equipment/Machinery + Value added + digitalized intelligence overall Plant Solutions and Service” (“MVP Solutions & Service”), bringing certainty to customers to achieve rapid commercial production and shorter time to market.
This strategic cooperation starts with the integrated modular plant of two important production facilities in the Singapore CRDMO Center of WuXi Biologics, and will include design, manufacturing, FAT, installation, commissioning and validation. The project will adopt a new generation of modular fabrication, and the majority of works will be built, assembled and FAT-tested in Morimatsu’s workshop. The quality, schedule, cost and risk of the project will be well managed and controlled. Compared with conventional construction, this method also greatly shortens the project cycle.
Chris Chen, CEO of WuXi Biologics, commented, “Singapore is one of the most advanced pharmaceutical hubs in the world, as well as a critical part of our global biomanufacturing network. By leveraging Pharmadule Morimatsu’s expertise and experience, we are confident that our Singapore CRDMO Center will contribute to our track record in establishing global sites successfully as demonstrated by our greenfield site in Ireland, further enabling global partners with premier quality services and solutions.”
Mr. Weihua Tang, CEO of Morimatsu LifeSciences, commented, “WuXi Biologics is an important partner of our company, we are very delighted to cooperate with them once again. In this cooperation, Pharmadule Morimatsu will utilize a new generation of modular fabrication methods to assist WuXi Biologics in expanding production capacity, accelerating the empowerment of global pharmaceutical companies, reducing R&D costs, and benefiting patients worldwide.”
.
. The chemical energy of a fuel is converted directly into electricity by a fuel cell generator, which is an electrical power generation system that makes use of fuel cell technology. It is made up of a stack of fuel cells and any supporting plant balance parts. Hydrogen is the most typical fuel used in fuel cell generators, while other fuels can also be utilized. Depending on the precise type of fuel cell technology being used, other fuels like methanol or ammonia can also be utilized.
